Hormone therapy can protect bone after menopause, but it is not the same decision as treating osteoporosis.
That distinction matters because bone loss, hot flashes, early menopause, and fracture risk often arrive in the same decade. The 2022 Menopause Society position statement says hormone therapy prevents bone loss and fracture. It also says the benefit-risk ratio is generally more favorable for healthy symptomatic women who are younger than 60 or within 10 years of menopause onset and have no contraindications. [4]
So the useful question is not "Is hormone therapy good for bones?" The useful question is: what bone-risk category are you in, and is hormone therapy the right tool for that category?
Short answer: hormone therapy can protect bone, but the category matters
Hormone therapy belongs in the bone-density conversation because estrogen loss accelerates bone loss after menopause. But it should be positioned carefully.
| Situation | Where hormone therapy may fit | What should happen first |
|---|---|---|
| Bothersome hot flashes or night sweats near menopause plus bone-loss concern | May be part of a symptom-and-prevention plan if age, timing, uterus status, route, dose, and contraindications fit. [4] | Hormone-therapy eligibility review. |
| Early menopause or premature ovarian insufficiency | Often discussed for risk reduction when no contraindication exists. | Diagnosis, fertility/contraception review, bone and cardiovascular risk review. |
| Low bone density without fracture | May be considered in selected candidates, but fracture probability still matters. | Bone-density scan, FRAX (Fracture Risk Assessment Tool) or clinical risk assessment, and secondary-cause review. [1] [2] |
| Osteoporosis-range bone density | Usually not a hormone-only plan. | Osteoporosis-specific treatment discussion. [2] [3] |
| Prior hip or spine fracture | Do not reduce this to menopause symptom treatment. | Fracture-risk treatment pathway, often regardless of bone-density scan result. [2] |
| High clot, stroke, heart, breast-cancer, liver, or unexplained bleeding risk | Systemic hormone therapy may be a poor fit or need specialist review. | Separate bone protection from hormone eligibility. [4] |
The practical mistake is using one phrase, "hormone replacement therapy for bones," for several different clinical categories.
What the 5-year bone-density study can and cannot tell us
One older source on this question was a 5-year prospective study of postmenopausal women who used hormone therapy and had yearly lumbar-spine bone mineral density measurement. The study enrolled 154 women; 136 completed the first year and were followed as spontaneous menopause or surgical menopause groups. Only 55 of the 136 women finished the 5-year follow-up. [5]
The direction was supportive: long-term hormone therapy increased lumbar-spine bone mineral density in women with spontaneous menopause and protected against bone loss in surgically postmenopausal women. [5]
That is useful, but it is not enough for a modern patient-facing article by itself.
| Evidence strength | What it supports | What it does not support |
|---|---|---|
| Prospective 5-year follow-up | Hormone therapy can preserve or improve lumbar-spine bone mineral density in a selected postmenopausal group. [5] | A broad claim that every route, dose, timing, or product prevents fractures equally. |
| Dropout: 55 of 136 completed 5 years | Long follow-up is valuable, but retention limits certainty. [5] | A one-size-fits-all promise for real-world adherence. |
| Lumbar-spine measurement | Spine bone density can respond to hormone therapy. | A full fracture-risk plan without hip, fall, fracture, medication, and FRAX context. |
The better modern frame is to use that study as one supporting piece, then anchor the plan in current screening and treatment guidance.
Screening decides whether this is prevention or treatment
Bone density after menopause should start with fracture-risk classification.
U.S. Preventive Services Task Force recommends osteoporosis screening for women 65 or older. It also recommends screening postmenopausal women younger than 65 when they have 1 or more risk factors and clinical risk assessment estimates increased fracture risk. Screening can include dual-energy X-ray absorptiometry, commonly called a bone-density scan, with or without fracture-risk assessment. [1]
That matters before a hormone decision because the same symptom can sit in different risk categories.
| Finding | What it usually means | Why it changes the hormone discussion |
|---|---|---|
| No screening indication yet | Bone prevention may focus on exercise, nutrition, fall prevention, and future screening timing. | Hormone therapy should not be started only because screening has not been done. |
| Early screening indication before 65 | Risk factors justify measuring bone density earlier. [1] | Hormone therapy is only one possible prevention tool. |
| Osteopenia | T-score between -1.0 and -2.5. | FRAX and clinical risk decide whether medication is needed. [2] |
| Osteoporosis-range result | T-score at or below -2.5 at key sites. [2] | This usually needs an osteoporosis-treatment conversation, not only symptom treatment. |
| Hip or vertebral fracture | The Bone Health and Osteoporosis Foundation supports treatment regardless of bone mineral density. [2] | Hormone therapy should not be the shortcut around fracture-risk treatment. |
| Osteopenia plus high FRAX | The Bone Health and Osteoporosis Foundation uses at least 3% 10-year hip fracture risk or at least 20% major osteoporotic fracture risk as common treatment thresholds. [2] | A person can need medication before the T-score reaches -2.5. |
FRAX is useful but incomplete. Falls, frailty, some medication exposures, spine-versus-hip differences, and secondary causes can change the decision. A borderline report still needs clinical context.
When hormone therapy is a reasonable bone-density discussion
Hormone therapy is most coherent for bone when it is part of a broader menopause plan, especially near the menopause transition.
The strongest fit is a woman with bothersome hot flashes or night sweats, no contraindications, and a bone-prevention concern near menopause. In that setting, the same therapy may address symptoms and help protect bone. [4]
The Endocrine Society gives a narrower osteoporosis-specific frame. It suggests menopausal hormone therapy for some postmenopausal women at high fracture risk when they are under 60 or less than 10 years past menopause, have low deep vein thrombosis risk, have bothersome vasomotor and other climacteric symptoms, have no contraindications, no prior heart attack or stroke, no breast cancer, and when bisphosphonates or denosumab are not appropriate. [3]
That is a long list because the selection is the point.
| Candidate feature | Why it matters |
|---|---|
| Younger than 60 or within 10 years of menopause onset | The benefit-risk ratio is generally more favorable in this window. [4] |
| Bothersome vasomotor symptoms | Hormone therapy has a strong symptom indication, not only a prevention rationale. [4] |
| Uterus status is known | Systemic estrogen usually needs endometrial protection when the uterus is present. |
| Low clot, stroke, heart, breast-cancer, and liver-risk profile | Contraindications can make systemic therapy inappropriate. [3] [4] |
| Bone-risk category is known | Prevention, osteopenia, osteoporosis, and prior fracture are not the same plan. [1] [2] |
| Follow-up is defined | Benefit, bleeding, side effects, dose, duration, and repeat bone-density timing should be reviewed. |
This is also why "natural estrogen for bones" is too vague. The decision is about exact hormone, route, dose, uterus status, timing, contraindications, evidence, and monitoring.
When osteoporosis-specific treatment should lead
If the main problem is established osteoporosis or prior fracture, osteoporosis-specific therapy usually moves to the center of the plan.
The Endocrine Society recommends treating postmenopausal women at high fracture risk, especially those with previous fracture. It recommends bisphosphonates as initial treatment for many high-risk postmenopausal women, denosumab as an alternative initial treatment, anabolic therapy for very high risk such as severe or multiple vertebral fractures, and monitoring bone mineral density every 1 to 3 years in high-risk patients with low bone density. [3]
The Bone Health and Osteoporosis Foundation similarly frames osteoporosis as a fracture-prevention condition. It lists pharmacologic-treatment thresholds that include a T-score at or below -2.5, hip or vertebral fracture regardless of bone density, and osteopenia with FRAX risk at least 3% for hip fracture or 20% for major osteoporotic fracture. [2]
| Higher-risk pattern | Why hormone therapy should not be the whole answer |
|---|---|
| Hip or vertebral fracture | Treatment is usually indicated regardless of bone-density scan result. [2] |
| Multiple fractures or very high risk | Anabolic or other osteoporosis-specific therapy may be considered. [3] |
| T-score at or below -2.5 | This meets osteoporosis-range bone density and needs fracture-risk planning. [2] |
| High FRAX with osteopenia | Medication may be reasonable before the scan reaches osteoporosis range. [2] |
| Denosumab use | Stopping or delaying denosumab without another antiresorptive plan can cause rapid bone loss and increased fracture risk. [3] |
Hormone therapy may still be part of a plan for a carefully selected woman, but it should not blur the difference between symptom treatment and fracture-risk treatment.
Compounded hormones: useful flexibility, but not a shortcut around evidence
Compounded hormone therapy should be discussed neutrally and precisely.
The U.S. Food and Drug Administration describes compounding as a licensed pharmacist, licensed physician, or supervised outsourcing-facility pharmacist combining, mixing, or altering drug ingredients to create a medication tailored to an individual patient's needs. FDA also says compounded drugs can serve an important medical need for certain patients. [6]
That matters in real care. A compounded preparation may be useful when an FDA-approved product cannot meet a documented need, such as an allergy to an inactive ingredient, a route problem, a swallowing issue, or a dose/formulation gap. That is personalization in the clinically meaningful sense: the medication can be adjusted to the particular patient and practical treatment barrier.
The boundary is equally important. FDA says compounded drugs are not FDA-approved, meaning FDA does not verify their safety, effectiveness, or quality before marketing. The American College of Obstetricians and Gynecologists clinical consensus on compounded bioidentical menopausal hormone therapy says compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist. [6] [7]
For bone density, that means:
| Compounding benefit | Evidence boundary |
|---|---|
| Dose, route, vehicle, or ingredient flexibility for a documented patient need. | The custom formulation itself does not establish fracture reduction. |
| Ability to avoid a problematic inactive ingredient or make a needed form. | Product quality, potency, and labeling are not verified through FDA approval in the same way as approved drugs. [6] |
| More individualized prescribing when approved options cannot meet the need. | Saliva-test or "balanced hormone" marketing should not replace symptom, risk, and bone-density assessment. [7] |
The balanced takeaway is that compounding has a role, and the role should be named.
Who this fits, and who should avoid waiting
This article fits women in midlife who are trying to understand whether hormone therapy belongs in a bone-density plan. It is especially relevant if hot flashes, night sweats, early menopause, ovary removal, osteopenia, or family fracture history are part of the same conversation.
It is not a fit for delaying care after a fracture, new spinal pain, major height loss, or an osteoporosis-range bone-density result. It is also not a fit for treating calcium, vitamin D, collagen, exercise, or hormone therapy as a substitute for fracture-risk medication when fracture risk is already high.
The care plan should classify the problem first:
- Routine prevention and future screening.
- Early screening before 65 because risk factors are present.
- Osteopenia with low, moderate, or high fracture probability.
- Osteoporosis-range bone-density result.
- Prior fragility fracture or very high fracture risk.
- Early menopause, premature ovarian insufficiency, or surgical menopause.
Hormone therapy may be reasonable in some of those categories. It is not the answer to all of them.
Red flags and higher-risk patterns
Do not treat these as routine menopause bone concerns:
| Pattern | Why it matters |
|---|---|
| Any low-trauma fracture after age 50 | The Bone Health and Osteoporosis Foundation describes adult fracture as a signal for further assessment and elevated future fracture risk. [2] |
| Hip or vertebral fracture | Treatment may be indicated regardless of bone-density scan result. [2] |
| Sudden back pain, height loss, or new spinal curvature | Vertebral fractures can be missed and can raise future fracture risk. |
| Long-term glucocorticoids, aromatase inhibitors, cancer therapy, organ-transplant medicines, or thyroid over-treatment | Medication-related bone loss can change screening timing and treatment choice. |
| Early menopause, premature ovarian insufficiency, or removal of both ovaries before the usual menopause age | Longer low-estrogen exposure can make bone protection more urgent. |
| Frequent falls, frailty, neuropathy, vision problems, sedating medicines, or balance problems | Fracture risk may be high even when bone density is not the only issue. |
| Unexplained vaginal bleeding, prior breast cancer, prior clot, stroke, heart attack, serious liver disease, or high-risk thrombophilia | These can change or block systemic hormone therapy. [3] [4] |
Red flags do not automatically mean medication is the answer. They mean the plan should be based on fracture risk, not reassurance.
What to ask a clinician
Ask questions that separate the bone plan from the hormone plan:
- Do I meet U.S. Preventive Services Task Force screening criteria now, or should screening wait until 65?
- Does my bone-density scan show normal bone density, osteopenia, or osteoporosis-range bone density?
- Should FRAX be calculated, and does it cross the 3% hip-fracture or 20% major-fracture threshold?
- Am I considering hormone therapy mainly for hot flashes with bone prevention as a secondary benefit, or am I treating osteoporosis?
- Am I younger than 60 or within 10 years of menopause onset, and do I have any contraindications?
- If systemic estrogen is considered, what is the endometrial-protection plan if I have a uterus?
- If a compounded option is discussed, what approved product cannot meet my need, and what dose, route, ingredient, or formulation problem is being solved?
- If I already have osteoporosis or a fracture, which osteoporosis-specific therapies are appropriate and why?
- What would trigger repeat bone-density testing or a change in treatment?
The answers should name the category, not just the product.
Bottom line
Hormone therapy can help protect bone density after menopause, and that benefit matters.
But the safest plan starts with fracture-risk classification. Screening criteria, bone-density scan results, FRAX, prior fracture, age, timing since menopause, contraindications, uterus status, and symptom burden decide whether hormone therapy is a good fit or whether osteoporosis-specific medication should lead.
Compounded hormones can have a real patient-specific role when approved options cannot meet a documented need. They should be framed as flexible formulations with specific boundaries, not as automatically safer or more evidence-backed bone-density treatments.
Related reading:
- Bone Density After Menopause.
- Hormone Therapy After Menopause.
- Starting Hormone Therapy After 60.
- Early Menopause Before 45.
- Bioidentical Hormone Replacement Therapy: FDA-Approved vs Compounded.
References
[1] U.S. Preventive Services Task Force. Osteoporosis to Prevent Fractures: Screening. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening
[2] LeBoff MS, Greenspan SL, Insogna KL, et al. The clinician's guide to prevention and treatment of osteoporosis. https://link.springer.com/article/10.1007/s00198-021-05900-y
[3] Endocrine Society. Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources. https://www.endocrine.org/clinical-practice-guidelines/osteoporosis-in-postmenopausal-women
[4] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[5] Castelo-Branco C, Figueras F, Sanjuan A, Vanrell JA. Long-term postmenopausal hormone replacement therapy effects on bone mass: differences between surgical and spontaneous patients. <(98)00313-3>. https://doi.org/10.1016/S0301-2115
[6] U.S. Food and Drug Administration. Human Drug Compounding. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
[7] Compounded Bioidentical Menopausal Hormone Therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol. 2023;142(5):1266-1273. doi:10.1097/aog.0000000000005395 https://pubmed.ncbi.nlm.nih.gov/37856860/